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ABSTRACT 
 
Background 
Patient and public involvement in research (PPIR) may improve trial recruitment rates, but it is unclear 
how. Where trials use PPIR to improve design and conduct, many do not communicate that clearly to 
potential participants. Better communication of PPIR might encourage patient enrolment, as trials may 
be perceived as more socially valid, relevant, and trustworthy.  We aimed to evaluate the impact on 
recruitment of directly advertising PPIR to potential trial participants.  
 
Methods 
A cluster trial, embedded within a host trial (‘EQUIP’) recruiting service users diagnosed with severe 
mental illness. The intervention was informed by a systematic review, a qualitative study, social 
comparison theory and a stakeholder workshop including service users and carers. Adopting 
Participatory Design approaches, we co-designed the recruitment intervention with PPIR partners using 
a leaflet to advertise the PPIR in EQUIP and sent potential participants invitations with the leaflet 
(intervention group) or not (control group). Primary outcome was the proportion of patients enrolled in 
EQUIP. Secondary outcomes included the proportions of patients who positively responded to the trial 
invitation.  
 
Results 
34 community mental health teams were randomised and 8182 service users invited. For the primary 
outcome, 4% of patients in the PPIR group were enrolled versus 5.3% of the control group. The 
intervention was ineffective for improving recruitment rates (adjusted OR= 0.75, 95% CI= 0.53 to 1.07, 
p=0.113). For the secondary outcome of positive response, the intervention was not effective, with 7.3% 
of potential participants in the intervention group responding positively versus 7.9% of the control 
group (adjusted OR=0.74, 95% CI= 0.53 to 1.04, p=0.082). We did not find a positive impact of directly 
advertising PPIR on any other outcomes.  
 
 
Conclusion 
To our knowledge, this is the largest ever embedded trial to evaluate a recruitment or PPIR intervention. 
Advertising PPIR did not improve enrolment rates, or any other outcome. It is possible that rather than 
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advertising PPIR being the means to improve recruitment, PPIR may have an alternative impact on trials 
by making them more attractive, acceptable and patient-centred. We discuss potential reasons for our 
findings and implications for recruitment practice and research.   
 
Trial registration numbers: 
ISRCTN: ISRCTN16488358 (14 May 2014) 
Study Within a Trial Registration Number: SWAT 26 (21 January 2016) 
 
Keywords 
Recruitment, Patient and public involvement, Research methodology, randomised controlled trial, 
service user involvement, study within a trial 
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BACKGROUND 
Randomised controlled trials are the gold standard for evaluating treatments, yet recruitment into trials 
remains a great challenge, with approximately 45% of publicly-funded and 80% of industry-funded trials 
failing to meet their recruitment targets [1], [2]. Mental health disorders are the leading cause of 
disability among adults worldwide [3], however trials enrolling patients with mental health problems 
experience even greater recruitment challenges [4]–[7]. These challenges stem from various sources 
including stigma [8] and issues related to the diagnosis adversely impacting on the patient’s ability and 
motivation to participate in research [9]. Inability to recruit into a trial adversely impacts trials by 
reducing the total sample size (which limits internal validity), and the proportion of eligible participants 
who are recruited (which limits external validity).  
 
Thus there is a need to develop and test interventions to improve recruitment. One method is to 
‘embed’ trials of recruitment interventions in ongoing trials; however such trials are rare. Systematic 
reviews of trial recruitment interventions have highlighted the need for more embedded recruitment 
trials [10], [11].  Recent initiatives have also increasingly called for the development and evaluation of 
interventions for recruiting and retaining participants in trials [11]–[16]. 
 
We have developed methodological, logistical and reporting frameworks for embedded recruitment 
trials [12], [17], and  assessed their feasibility using interventions such as an improved participant 
information sheet and a multimedia decision aid [18], [19]. The eventual aim is to make delivery of 
embedded recruitment trials a routine activity, to assist the rapid development of recruitment to meet 
health and policy goals [20].  
 
Patient and public involvement in research (PPIR), also known as ‘user involvement’ among others, is 
research being carried out ‘with’ or ‘by’ patients and/or members of the public rather than ‘to’, ‘about’ 
or ‘for’ them [21]. This definition of PPIR is broad, and involves patients, all groups who represent 
patients, as well as members of the public taking roles in the development, conduct and governance of 
research [22]–[24]. PPIR is thought to be crucial because it produces ‘better’ patient-focused research by 
offering unique, invaluable insights into its prioritization, design, implementation and evaluation, 
making trials more effective and credible [25], [26]. PPIR is well-established as public policy in the United 
Kingdom (UK) and other developed countries and is increasingly mandated for publicly-funded trials 
[27]–[30]. However, quantitative evidence around its impact is sparse, and that which exists is of poor 
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quality and lacking in rigour [31]. There is a need to  assess the effectiveness, cost effectiveness and 
ethical impacts of PPIR through high-quality methodological research [31]–[37]. 
 
We recently reported a systematic review and meta-synthesis of factors affecting the recruitment of 
participants into depression trials [38] to help us develop and evaluate an intervention for recruiting 
participants into mental health trials, using the Medical Research Council (MRC) complex interventions 
framework [39]. We developed a conceptual framework, which highlighted that the decision by patients 
to enrol as subjects in trials involves a difficult deliberation involving ‘risk’ [38]. This includes potential 
risks of stigma, of ‘losing out’ by being randomised to the ‘wrong’ intervention arm, or of encountering 
adverse effects of trial involvement, against potential rewards such as a personal need to access 
treatment and support. Outside of the mental health context, perceptions of risk have also been shown 
to impact on patients’ decision to enrol in trials [40]–[44]. We have also undertaken a qualitative study 
with patients who declined to participate in a trial, which highlighted the need to research the 
presentation and provision of accurate and effective trial information in which patients and the public 
play a seminal role [45].  
 
There is some emerging observational evidence that mental health trials with more PPIR are associated 
with an increased likelihood of achieving their recruitment targets [46], although studies in other clinical 
settings have had variable outcomes [47].  PPIR may have a role in reducing patient perception of risk in 
trials and as a consequence may increase trial enrolment. Patients may perceive trials with PPIR to be 
improved methodologically or ethically, or more relevant and therefore more likely to influence practice 
in ways that are important to them and other patients [25], [26], [48]. Additionally, the concept of 
‘social validation’ suggests that people may be more willing to comply with a request to enrol in a trial if 
they believe that others are already engaged in a trial, as people tend to compare and base their beliefs, 
attitudes and actions on  similar others [49]–[51]. A survey of public attitudes to research suggests that 
PPIR may increase confidence and trust in a trial, if potential participants are reassured that other 
patients have advised its design [52], [53]. The authors concluded that: ‘if health researchers 
communicate the fact that patients and the public have been involved in the design of their research 
when approaching potential study participants, it might help to boost recruitment’ [52], [53]. However, 
to achieve these effects, it is necessary that PPIR is communicated to patients, but this does not always 
seem to be the case as researchers tend not to routinely advertise PPIR [54], [55]. We aimed to test this 
hypothesis about the effects of PPIR on recruitment using a rigorous evaluation. In this paper, we 
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describe the development and evaluation of an intervention directly advertising PPIR in a mental health 
trial to potential participants. 
 
OBJECTIVES 
Our objectives were: to work with PPIR stakeholders to develop an intervention directly advertising PPIR 
in the design and conduct of a host trial, the ‘Enhancing the quality of user involved care planning in 
mental health services’ (‘EQUIP’) trial, which was recruiting people with a diagnosis of severe mental 
illness; and to evaluate its effectiveness on recruitment by undertaking a randomised controlled trial, 
embedded in the EQUIP host trial. 
 
METHODS 
We report the development of the intervention in line with the Criteria for Reporting the Development 
and Evaluation of Complex Interventions (CReDECI 2) [56] and its evaluation in line with the guidelines 
for reporting embedded recruitment trials [17].  
 
Trial design: the EQUIP host trial 
The EQUIP trial aimed to recruit 480 service users with diagnoses of severe mental illness to evaluate 
the cost-effectiveness of a training intervention for mental health professionals in enhancing user 
involvement in care planning. EQUIP had significant high-quality PPIR and was awarded the 2014 UK 
Mental Health Research Network Prize for ‘Outstanding Carer Involvement’ [57]. 
 
EQUIP is a multi-centre cluster randomised trial, where 36 community mental health teams in the 
Midlands and North of England were randomly allocated to training or to usual care. In EQUIP mental 
health team clusters were ‘paired’ at the recruitment stage (based on size and geographic location) and 
randomised using minimisation in pairs to training or the control arm. Recruitment in the paired clusters 
then operated in parallel. 
 
EQUIP used existing registers maintained by community mental health teams to recruit service users. 
Recruitment was undertaken by the UK Clinical Research Network Mental Health (CRN MH) Clinical 
Studies Officers (CSOs) and research nurses, who, in conjunction with service users’ Care Coordinators, 
were responsible for accessing service user details, determining eligibility and mailing trial invitations. 
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Invitations were posted to patients before randomisation of mental health teams occurred in EQUIP. To 
be eligible,  patients had to be: aged 18 years or older; under the care of the  community mental health 
team; have capacity to provide fully informed consent; and judged by their Care Coordinator to be well 
enough to complete study assessments. The research team did not have access to service users’ details 
until service users returned the ‘consent to contact’ form. In the majority of mental health teams, 
potential participants who did not respond to the initial invitation letter were telephoned by a CSO or a 
member of their mental health team to determine whether they received the trial invitation and 
whether they were interested in taking part. Recruitment and baseline assessment of participants within 
each cluster occurred within a six-week period, before the training was delivered to the mental health 
clusters in the intervention arm. The EQUIP team aimed to recruit a minimum of 10 participants per 
cluster (no upper limit was specified). Details of the EQUIP trial design have  been reported elsewhere 
[58].  
 
 
Trial design: the embedded recruitment trial  
 
Recruitment into the embedded trial occurred over an 18-month period (June 2014-December 2015) 
until recruitment into the host trial ceased. A patient-level randomised controlled trial would have been 
the most efficient design for the embedded recruitment trial; however this was not practical as it was 
logistically burdensome for the EQUIP host trial team to administer. We therefore adopted a cluster 
randomised design for the recruitment trial, using the same mental health team clusters as in the EQUIP 
host trial.  This had two methodological implications. First, due to the relatively small numbers of 
clusters (n=36), there was a possibility of imbalance between the patients in the two arms of the 
embedded trial. Second, there was also a potential risk to the validity of the host trial: if the PPIR 
recruitment intervention were successful, there could be differences between arms in the numbers and 
types of patients enrolled into the host trial.  
 
We therefore adopted a cross-factorial embedded randomised controlled trial design with the EQUIP 
host trial intervention allocation, using pairwise allocation. In the embedded trial, the same cluster pairs 
as in the EQUIP host trial were presented for randomisation; however we randomised both clusters to 
receive the PPIR intervention, or both to the control arm (as opposed to one cluster being assigned to 
the intervention arm, and the other to the control arm). The priority was to ensure the integrity of the 
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host trial. Pairwise allocation guaranteed that we achieved balance of cluster allocations between 
interventions and control arms for both the EQUIP host trial and for the embedded recruitment trial; 
this allocation method also ensured the validity of both the host and embedded recruitment trial 
interventions.  
 
Clusters were randomly allocated for their patients to be sent one of two interventions: the standard 
invitation (control group); or the PPIR intervention in addition to the standard invitation (intervention 
group). The PPIR intervention was sent in the same envelope as the EQUIP trial invitation, which also 
contained a cover letter, a participant information sheet, a ‘consent to contact’ response form and 
stamped addressed envelope. The embedded recruitment trial thus measured the incremental benefit 
of being sent the recruitment intervention. Figure 1 outlines the recruitment flowchart for the 
embedded recruitment trial. 
 
Eligibility criteria for participants: embedded recruitment trial 
The recruitment trial included all patients identified as potentially eligible for the EQUIP host trial: there 
were no additional inclusion or exclusion criteria.  
 
The recruitment intervention: The PPIR communication and its development 
We developed a recruitment intervention communicating PPIR guided by the MRC complex 
interventions framework [39], informed by Participatory Design approaches with end users [59], [60]. As 
described earlier, the hypothesised mechanism was reducing the perception of risk in trial enrolment, 
informed by our prior systematic review [38] and qualitative study [45],‘social validation’, emerging 
from social comparison theory [49], [51] and survey evidence [52], [53]. We searched the latest 
Cochrane systematic reviews to determine frequently used recruitment and retention interventions 
[11], [61]. We reviewed the EQUIP host trial recruitment strategy and held discussions with the EQUIP 
team to determine a simple, systematic, feasible and acceptable method of delivering the PPIR 
intervention. Given that the recruitment occurred through mental health teams and patients were being 
approached to enter the host trial by postal invitations, we selected a leaflet format as the delivery 
mechanism to communicate PPIR. We then organised an expert workshop involving 27 key stakeholders 
including 10 service users with severe mental illness and two carers of people with severe mental illness, 
who were either EQUIP PPIR members or belonged to the EQUIP trial target population. Other 
stakeholders present were: five principal investigators/researchers with expertise in undertaking mental 
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health trials; three patients with physical health problems; two researchers with expertise in PPIR; two 
mental health trial recruiters; two research ethical review board members and a consultant psychiatrist . 
 
During this workshop, stakeholders endorsed the use of the of the leaflet format for advertising PPIR 
with the aim of improving recruitment. Working in small breakout groups (each group comprised of a 
mix of researchers and PPIR members), and then reconvening, stakeholders discussed and agreed seven 
‘core principles’ for the leaflet advertising PPIR to potential trial participants (see Table 1). 
 
Table 1: Core components of the PPIR communication leaflet intervention 
[Table 1 about here] 
 
1. The intervention advertising PPIR was in a leaflet format ;  
2. The leaflet was in a booklet style;  
3. The leaflet was written in plain language, with an informal, conversational style;  
4. The leaflet included photographs of the PPIR patients and carers, who in their own voice 
describe how they were involved in the trial and what their impact has been;  
5. The leaflet included photographs of the research team; 
6. The leaflet aimed to show that PPIR was taken  seriously and not tokenistic, and aimed to 
provide an honest account of PPIR; 
7. The leaflet aimed to be eye catching: bold, bright print, large font, colourful 
 
 
 
In line with the principles of Participatory Design, participants were asked to design their ideal PPIR 
leaflet according to the ‘core principles’ in four break-out groups using appropriate materials. Each of 
the four groups presented their prototype leaflets to the wider group, including the key elements of the 
design. Members then voted for which of the four leaflets they thought was best overall for attracting 
potential participants. The top-rated leaflet contained similar elements to the other leaflets, including: 
making a clear and direct appeal for potential participants to join the trial; positive photographs of 
people with mental health problems which avoided the typical media image of people holding their 
heads in their hands, which members discussed as stigmatising [62]; highlighting benefits to future 
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patients and convenience; the option to withdraw from the trial without giving a reason; and approval 
by an independent research ethics committee. 
 
Two of the PPIR members of EQUIP who were present at the workshop (LC and DM) - one a carer and 
the other a service user - volunteered to be photographed and featured in the EQUIP PPIR leaflet. Both 
PPIR members had active and ongoing involvement in EQUIP, one as a co-applicant and a member of the 
trial management team; and both as part of the training team who delivered the user-involvement 
training intervention to the host trial intervention clusters. We worked closely with LC and DM to 
develop a bespoke leaflet for the EQUIP host trial, in line with the ‘core principles’ and taking into 
account key elements from the four leaflets created during the workshop. Once the initial version was 
developed, we asked for contributions from the EQUIP host trial researchers (chiefly to check for 
accuracy); their input did not change the content or format of the leaflet. The leaflet was then sent to a 
professional graphic designer in a company with significant expertise in designing patient 
communication materials (www.makingsense.co.uk). The design brief highlighted the agreed ‘core 
principles’ (Table 1) and related solely to the visual presentation of the leaflet and not the content. Two 
versions of the leaflet were initially designed and presented to the EQUIP team and PPIR members, who 
voted on their preferred design. Voting gave priority to PPIR members, who also provided comments in 
three rounds of iterations before the final design was agreed. These comments related to the colours 
and visual presentation, and the content did not change. Table 2 outlines the presentation and content 
of the final leaflet, which is also attached as Appendix 1. 
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Table 2: Content and layout of the finalised PPIR leaflet 
[Table 2 about here] 
 
Presentational elements Content 
 Four-page booklet format 
 Photographs of the EQUIP trial 
team together with PPIR 
members on the front and back 
pages 
 Written in plain language; 
informal, conversational style 
 Contained several photographs 
of the PPIR members, including 
one of them designing the leaflet  
 Quotations written by PPIR 
members  
 Use of large font sizes and bright 
colours  
 Front and back pages advertised award of 
‘outstanding carer involvement’ to EQUIP 
 Front page stated that ‘real patients and carers’ had 
informed in the design of the study, and asked 
patients to consider taking part in EQUIP  
 Middle pages of the leaflet contained Photographs 
of PPIR members  
 Quotations by PPIR members described why they 
thought the study was important 
 A section highlighting issues felt to be important to 
patients including: helping future patients, 
convenience, confidentiality, approval by a research 
ethics committee 
 Quotation by EQUIP chief investigator about close 
working with PPIR members 
 Contained contact details of the study team 
 
 
 
Outcome measures 
 
In the EQUIP host trial, CSOs or mental health teams telephoned patients who did not initially respond 
to the postal invitation in poor recruiting clusters. There is evidence that telephone follow-up prompting 
of patients who do not respond to invitations to participate in trials significantly increases recruitment 
[11]. The host trial recruiters undertook telephone follow-ups as and when necessary, which meant not 
all clusters had the telephone follow-ups.  
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Our pre-planned primary outcome was therefore chosen to assess the effect of the PPIR leaflet, without 
potential contamination of the telephone follow-ups. The primary outcome for our embedded 
recruitment trial was the proportion of participants in each group who were consented and enrolled into 
the EQUIP host trial after responding to the postal invitation (i.e. the proportion of participants who 
responded and enrolled without the need for a telephone follow-up reminder).  
 
The secondary outcomes were:  
 
1. The proportion of patients in each group  who positively responded, without the need for a 
telephone follow-up reminder (Note this differs from the number actually consented and 
enrolled, due to for instance, the EQUIP trial exclusion criteria);   
2. The total proportions of patients in each group who were consented and enrolled, including 
telephone follow-up of initial non-responders 
3. The numbers of clusters in each group needing to conduct telephone follow ups due to low 
postal response. This outcome takes into account the potential resource implications of a 
mental  health clinician or a trial recruiter telephoning patients who do not respond to the trial 
invitation 
 
Sample size calculation 
 
The sample size calculations for the EQUIP trial have been published in the original protocol [58].  
 
As is usual with a trial embedded within a host trial, we did not undertake a formal power calculation to 
determine the sample size [15], since the sample size was constrained by the number of mental health 
teams and patients being approached in the EQUIP host trial. Our sample size was the total number of 
service users invited to participate in EQUIP from the 34 available clusters at the time of implementing 
the embedded trial, which was 8182 potential participants. We did not undertake a post-hoc power 
calculation as this is arguably a futile exercise, since the power of a trial is expressed in the confidence 
interval generated from the outcome analysis [63] (see ‘results’ section). 
 
Randomisation 
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Randomisation was undertaken by the host trial statisticians (NO’L and CR), who were independent from 
the delivery of the trial interventions for both the host and embedded recruitment trials.  
Randomisation in the EQUIP host trial was stratified by cluster pairing, the site/region of each cluster 
and the caseload size of each cluster. For the recruitment trial, we used the same cluster pairing as the 
host trial and allocated each cluster pair by block-randomisation with permuted block sizes of 2, 4 and 6, 
using a computerised randomisation programme. Service users did not know that they were part of a 
trial of a recruitment intervention so were blind to the study hypothesis.  CSOs and research nurses 
undertaking trial recruitment and mental health team clusters were also blind to the group to which 
clusters were allocated.  
 
Statistical methods  
We obtained baseline data on cluster size (patient list size), deprivation, care quality rating and patient 
satisfaction with clinical care.  Deprivation used the Index of Multiple Deprivation (IMD) rank averaged 
across Lower-layer Super Output Areas for each cluster’s Clinical Commissioning Group [64]. Care quality 
and patient satisfaction data were obtained at the cluster level from the Care Quality Commission, 
which is the independent regulator of health and social care in England [65]. Patient satisfaction focused 
on the experiences of service users who receive care and treatment within the mental health teams. 
Preliminary graphical and tabular examination of the data explored baseline comparability of trial arms 
and representativeness of the sample in terms of the clusters and the overall eligible population.   
 
Data analysis used generalised linear mixed models [66] to estimate the effect of the recruitment 
intervention. As the unit of randomisation was the cluster pair, we fitted a three-level random effects 
logistic model, which pertained to the individual patient, clustered within mental health teams, 
clustered within paired mental health teams. We adjusted for mental health team cluster size, levels of 
deprivation and care quality rating (we did not include patient satisfaction with clinical care in the model 
due to incomplete data). We present the marginal mean difference in proportions, as well as odds 
ratios, to assist with interpretation. Standard errors and confidence intervals for cluster marginal effects 
were calculated using the Delta Method. Given that the EQUIP randomisation occurred after the 
embedded trial randomisation, there was no plausible causal effect of the EQUIP intervention on 
recruitment so we did not test for an interaction between the EQUIP intervention and the recruitment 
intervention. Fisher’s exact test was used to test for association between recruitment trial arm and the 
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need for telephone follow-up. Analyses used the intention-to-treat principle and were conducted using 
Stata, version 14 (Stata Corp., College Station, Texas, USA).  
 
RESULTS 
38 community mental health team clusters were recruited and randomised. One cluster pair (two 
clusters) could not be included as the EQUIP recruitment started before the embedded trial could begin. 
Another cluster pair withdrew from the EQUIP trial after randomisation, but prior to the mailing of 
invitation letters to their patients and are not included in the analysis. 8182 patients in 34 clusters were 
sent the standard EQUIP trial invitation letter or the addition of the PPIR intervention - see Figure 1, flow 
for embedded recruitment trial. Table 2 outlines the characteristics of the mental health clusters and 
patients. Comparison of cluster baseline characteristics showed that clusters in the intervention arm 
were larger (544 mean patient list size vs. 323); located in more deprived areas (IMD quintile median 1.5 
vs. 2.5); and had fewer mental health team clusters rated as ‘good’ for care quality (11.1% vs. 18.8%). 
Patients in the intervention and control arms were broadly similar in age and gender distribution.  
 
Primary outcome 
For the primary outcome of the proportions consented and enrolled into the EQUIP trial, 4% of patients 
sent the PPIR communication were enrolled compared with 5.3% of the control group (Table 3). Mixed 
effects logistic regression showed that the recruitment intervention was not effective for improving 
recruitment rates [Odds Ratio = 0.75, 95% CI (0.53,  1.07), p=0.113]. The average marginal effect of the 
intervention on the probability of enrolment was -0.0123 [95% CI (-0.0282, 0.0036)]. 
 
Secondary outcomes 
1. Positive response to the invitation, without telephone follow-up: There was no difference 
between the intervention and control groups, with 7.3% of potential participants sent the 
recruitment intervention responded positively, compared with 7.9% in the control group, 
adjusted OR=0.74, 95% CI= 0.53 to 1.04, p=0.082. The average marginal effect of the 
intervention on the probability of positive response was -0.0208 [95% CI (-0.0451, 0.0035)]. 
2. All positive response (inc. telephone follow-up): There was no difference between the 
intervention and control groups, with 9.2% of the intervention group responding positively, 
compared with 10.0% in the control group, Odds Ratio = 0.74, 95% CI= 0.51 to 1.09, p=0.125. 
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The average marginal effect of the intervention on the probability of all positive response was -
0.0343 [95% CI (-0.0795, 0.0108)]. 
3. Number of clusters requiring telephone follow up of non-responsive patients: This showed there 
was no association between the recruitment trial arm and the need for a telephone reminder, 
with 66.7% in the PPIR group, compared with 75% of control group, Fisher’s exact p-value = 
0.715. 
 
Figure 1: Flow diagram for embedded recruitment trial 
[Figure 1 about here] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No response 
(n=2580, 92.1%) 
 
PPIR Group 
 9 cluster pairs (n=18 clusters) 
 List size of CMHTs = 10785 
(mean 599, range 96 - 1230) 
Control group 
 8 cluster pairs (n=16 clusters) 
 List size of CMHTs = 6100, 
(mean 381, range 85 - 1389) 
Patients mailed trial invitation 
(n=2800, 34.2%) 
 
Patients mailed trial invitation 
(n=5382, 65.8%) 
 
No response 
(n=4988, 92.7%) 
 
Positive response 
(n=220, 7.9%) 
Telephone follow up of non-
responders (12 clusters, n=1552) 
 Positive response (n=168) 
 Negative response (n=1384) 
 
Telephone follow up of non-
responders (12 clusters, n=2968) 
 Positive response (n=259) 
 Negative response (n=2709) 
Consented and 
enrolled (n=92, 5.5%) 
 
Consented and 
enrolled (n=129, 4.6%) 
 
Total No. of community mental health teams (CMHTs) in 
all sites in EQUIP host trial (19 cluster pairs = 38 clusters) 
No. of CMHTs randomized (18 cluster pairs =36 clusters) 
Recruitment completed prior to start 
of embedded recruitment trial (1 
cluster pair = 2 clusters) 
Dropped out after allocation (1 
cluster pair = 2 clusters) 
 
Consented and 
enrolled (n=148, 5.3%) 
 
Consented and 
enrolled (n=216, 4%) 
 
Positive response 
(n=394, 7.3%) 
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Table 3: Baseline information for mental health cluster teams and patients, by allocation 
[Table 3 about here] 
 
                           Mental health team cluster  
Baseline factors 
PPIR group Control group 
List Size, mean (SD) 544 (273) 323  (191.6) 
IMD Quintile, median (range) 
[1=Most deprived; 5=least deprived] 
1.5 (1-4) 2.5 (1-5) 
Care Quality Commission Rating  
Good, n (%) 
Requires improvement, n (%) 
Rating suspended, n (%) 
Not yet inspected, n (%)  
 
2 (11.1%) 
8 (44.4%) 
8 (44.4%) 
0 (0%) 
 
3 (18.8%) 
6 (37.5%) 
4 (25%) 
3 (18.8%) 
Patient Satisfaction with Carea, mean (SD)  
[10=highly satisfied] 
6.6 (0.3) 6.9 (0.2) 
Patients expressing interest*: 
   Males, n (%) 
 
   Females, n (%) 
 
151 (38.9%) 
 
237 (61.1%) 
 
81 (36.8%) 
 
139 (63.2%) 
Patients Enrolled*: 
   Males, n (%) 
 
   Females, n (%) 
 
  Mean age, years (SD) 
 
76 (36.2%) 
 
134 (63.8%) 
 
48.5 (12.8) 
 
49 (36.0%) 
 
87 (64.0%) 
 
45.5 (9.3) 
a
Patient satisfaction survey score data available for 32 clusters.  
IMD = Index of Multiple Deprivation 
SD=standard deviation.  
* Baseline information only available for observed sample and not for entire cluster. 
 
 
Harms 
 
We tested a two tailed hypothesis, which accepted that sending the recruitment intervention to 
potential participants could cause benefit or loss to recruitment for the host trial. Patients not being 
recruited presents a loss to the host trial; however for the patient, not being enrolled into the trial may 
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not be harmful and may in fact be the best thing for them to make an informed decision that suits them 
without encountering the potential inconvenience or negative consequences of trial participation. The 
primary and secondary outcomes were designed to demonstrate any potential harms to the EQUIP host 
trial in terms of reduced enrolment in the intervention group. The results demonstrate that the 
recruitment intervention was ineffective for increasing enrolment rates for all outcomes measured. A 
second potential harm to the host trial was the potential differences in the numbers and types of 
patients enrolled into the host trial between the intervention and control groups. We sought to 
minimise this potential harm by adopting the cross-factorial design, and making baseline comparisons 
between the intervention and control groups. Baseline comparison of the intervention and control 
groups found no differences. We did not measure other potential harms, such as perceptions of 
increased pressure to participate in the intervention group. 
 
 
 
Discussion 
Summary of main findings 
We undertook an embedded trial to evaluate the effectiveness on recruitment of directly advertising 
PPIR to potential trial participants. In this group of patients with severe mental health problems, the 
overall rates of response and participation were low, although this was in line with similar studies [18]. 
For our primary outcome, we found that being sent the intervention was ineffective for improving 
recruitment rates. Our secondary outcomes found that directly advertising PPIR did not make a positive 
difference to any other outcomes. 
 
Strengths and limitations 
To our knowledge, this multi-centre trial involving 8182 patients is the largest ever trial embedded in an 
ongoing trial to have been undertaken to evaluate the effectiveness of an intervention on trial 
recruitment [11] as well as the largest to evaluate the impact of patient and public involvement [31], 
[47]. Recruitment trials embedded within host trials are often plagued by the problem of small sample 
sizes, as embedded trials are reliant upon the numbers of patients approached by the host trial. These 
numbers are not usually sufficient to show small but important differences in recruitment [11], [15].  
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The EQUIP host trial had award-winning high-quality PPIR. Additionally, the development of the 
recruitment intervention and its evaluation involved close collaboration with PPIR members. Both PPIR 
and recruitment are considered complex interventions [55], [67]. In our trial we used the MRC complex 
interventions framework to systematically develop a theory-informed recruitment intervention and 
evaluate it in a rigorous way, using real patients being approached to make a real decision about 
participation in an ongoing trial. With increasing calls and now guidance for measuring the impact of 
PPIR [68][69], our work provides randomised evidence in a field that is very much lacking such evidence.  
 
 
Cluster randomised designs are often used to evaluate the effectiveness of recruitment interventions 
[70]–[72], as they are often the most logistically feasible way to deliver recruitment interventions 
embedded in ongoing host trials. We recognise that cluster randomised trials can be susceptible to a 
range of methodological problems [73], [74]. Due to logistic and operational reasons, it was not possible 
to undertake a patient level randomised trial, so we adopted a cluster randomised trial design, which 
was a design agreeable to the host trial team, and protected the host trial from potential biases 
introduced by the recruitment intervention, such as differential recruitment and imbalance in 
characteristics of patients recruited into the host trial as a consequence of the PPIR intervention. The 
outcome of the random allocation led to there being more and larger clusters in the intervention arm of 
the recruitment trial. However this imbalance was a result of the random allocation and occurred by 
chance. This was a compromise and without this design we would not have been able to conduct the 
embedded recruitment trial, and we later adjusted for cluster size in the analyses. The randomisation of 
matched cluster pairs also has some potential problems, such as some pairs of clusters being more 
closely matched than others, so minimisation in this instance may have been a better option. However, 
again it was not feasible to undertake the minimisation because logistically, the least burdensome 
option for the host trial team was to use the same cluster pairs that they were using in the host trial.  
 
There is an argument that the impact of involvement within any particular project is somewhat 
unpredictable, and that there is a need to provide details of context in accounts of PPIR [75]. 
Furthermore, there is also a need to understand how context and mechanism influence the impact of 
PPIR [75]. We did not have sufficient resources to undertake formal qualitative interviews to understand 
the mechanism of impact. However we are currently undertaking two other embedded trials of this 
intervention directly advertising PPIR to potential trial participants to better understand the context and 
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mechanism of impact. In one of these linked trials, we are undertaking user-testing of the PPIR 
recruitment intervention with patients and families to enable the revision and refining of the 
intervention to make it more appropriate to their context. We are also undertaking qualitative 
interviews with people who enter the host trial to explore their views of the PPIR intervention and 
determine its impact on their decision making. 
 
 
Comparison with existing literature 
 
Our findings contrast with a survey where 44% members of the British public responding to a 
hypothetical question indicated that they would be more likely to enrol in a trial if they found that 
patients had advised in its design [53]. The authors of this survey reported that very few people thought 
PPIR would reduce their confidence in a trial. We found that patients actually invited to enter a real trial 
were no more likely to enrol when they were sent a leaflet about PPIR. Research investigating 
hypothetical and actual willingness to enrol in a trial found that only 20% of participants stating 
hypothetical willingness to enter a trial actually enrolled and that statements of hypothetical willingness 
to participate in future trials may overestimate true enrolment [76].  
 
A systematic review to assesses the impact of PPIR on recruitment and retention in trials has found that 
while PPIR is consistently associated with improved retention, the evidence for impact on enrolment is 
variable and inconsistent [47]. A number of studies identified by this review found either no significant 
positive effect of PPIR on trial recruitment, or in one case involving the recruitment of African-Americans 
being recruited through three different sources, that the non-PPIR arm was more effective at improving 
recruitment [77]. Our present findings are therefore in line with the literature evaluating the impact of 
PPIR on recruitment.  
 
Explaining our findings and potential mechanisms of action  
 
Beyond advertising PPIR intervention simply being ineffective for improving trial recruitment and 
response rates, there are a range of other possible reasons for our present findings. First, it is possible 
that people in the PPIR arm did not read the leaflet. The leaflet was sent by post in a large recruitment 
pack with several other documents. Those sent the recruitment pack may not have opened it, and those 
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that did may not have read the PPIR recruitment leaflet.  We were not able to determine how many 
people read the recruitment leaflet, and our intention to treat analysis may have underestimated the 
effects of the active intervention components.  
 
Second, it is also not clear whether those sent the leaflet who read it understood the message in the 
leaflet, and what PPIR meant for the trial they were being asked to enrol into. Conversely, there is some 
research evidence indicating that patients receiving supplementary written information about a trial in 
the form of a booklet or leaflet have improved knowledge about the trial [78], [79]. It is possible that 
those who read the leaflet were more likely to make a more informed decision about not enrolling in the 
trial, which would have been a good decision for the patient, but a bad outcome for the trial. 
Unfortunately in this population, it was not possible to obtain estimates of effect of the recruitment 
intervention for those who were randomised to receive the leaflet, who also actually read it, and how 
they interpreted the message.  
 
Third, there are a range of mechanisms by which PPIR might influence recruitment, including on the trial 
design and trial conduct. Thus the role of PPIR  might lead to sensitive issues being handled better [80] 
or enhance trial quality and appropriateness, making them more effective  [25], [35]. These mechanisms 
call into question the mechanism used in our trial, which is that advertising PPIR might improve 
recruitment. Additionally, the high-quality PPIR in EQUIP may have meant that the PPIR benefits may 
have been already optimised in EQUIP. The addition of the PPIR recruitment intervention may therefore 
have been irrelevant since the PPIR undertaken in EQUIP may have been sufficient to promote 
participant recruitment. However, the overall enrolment rates in EQUIP were low, with rates similar to 
other trials recruiting from similar populations [18][81], so this does not suggest that the significant PPIR 
in EQUIP improved recruitment when compared with other trials. This contrasts with an observational 
study which found that studies that involved patients to a greater extent were more likely to have 
achieved recruitment targets [46]. 
 
Fourth, we developed our conceptual framework around the decision to enter trials using depression as 
the case exemplar, yet our recruitment intervention, informed by the conceptual framework, was 
evaluated in a population of patients with severe mental illness (who may or may not have had 
depression). Depression is the leading cause of disease burden worldwide [82], [83], and when we 
initiated our programme of work, we anticipated that we would develop and then test the recruitment 
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intervention using a depression trial. However, we found it impossible to recruit a host depression trial 
in order to evaluate the recruitment intervention, despite directly contacting 14 potential host trials 
registered on the National Institute for Health research (NIHR) trials portfolio, seeking support from the 
Clinical Research Network Mental Health, who contacted trials on our behalf, and advertising for host 
trials via the UK Trial Managers’ Network. The main reason why a depression host trial was not 
forthcoming was due to a mismatch between the recruitment timelines of potential host trials and that 
of the embedded recruitment trial: the majority of host trials approached were either close to finishing 
participant recruitment, or were in the early phase of set-up, meaning it was not possible to align host 
trial participant recruitment with the embedded recruitment trial. Two other depression trials reported 
that they already intended to advertise their PPIR activities to potential participants. This failure to 
recruit a depression trial may have impacted on the embedded trial outcomes as the intervention may 
not have been as relevant for the population in the EQUIP trial of people with severe mental illness.  
However, approximately 47% of the EQUIP population had comorbid depression. Additionally, mental 
health disorders in general have the strongest established history of PPIR in the UK [84]–[86], and there 
is some evidence that the use of PPIR is significantly associated with successful recruitment across a 
range of mental health trials, including severe mental illness, psychoses and depression [87], [88]. 
Furthermore, the Health Research Authority survey suggesting direct communication of PPIR to 
potential participants indicated that this approach could be used in all disease areas [52], [53]. We 
developed the PPIR intervention closely with the EQUIP trial, and the use of the intervention was 
strongly endorsed by stakeholders.  
 
Fifth, we used the concept of social validation to inform our recruitment intervention. The concepts of 
risk and social validation exist across all disease areas however, not just depression. Social validation has 
also been used successfully as a trial recruitment intervention, with an embedded recruitment trial of 
text messages containing quotes from existing participants significantly increasing randomisations [89]. 
However in our trial, social validation came from patients as research partners, rather than from 
patients as trial participants. This may have had an influence on our findings.  
Finally, informal discussions of our findings with stakeholders suggested that the stigma associated with 
mental illness may have led to a negative impact of the PPIR intervention.  Stigma, both towards  others 
with mental health problems, as well as mental health stigma ‘internalised’ towards the person’s own 
self are well-documented and can deter people with mental health problems from seeking healthcare 
[90], [91][92]. In our recruitment trial, stigma may have meant that awareness that EQUIP had 
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significant PPIR from individuals with mental health problems may have made some people reluctant to 
enrol. Additionally, there may have been a perception of a lack of ‘professionalism’ in trial design and 
conduct, suggested by the significant involvement of patients and carers, as opposed to the trial being 
wholly conducted by ‘trained professional researchers’. Stigma and a perceived lack of professionalism 
may have combined to make some people disinclined to enrol in the trial. Other PPIR members and 
stakeholders involved in other trials suggested that the leaflet lacked representativeness and 
commented that the images of people in the leaflet were not representative of them, that: ‘the people 
in this leaflet do not look like me’. Diversity in representativeness of PPIR members has been discussed 
in the literature, and arguments have been made for the need to engage with PPIR representatives who 
reflect the diversity of the study population [93]. Due to resource constraints, we were unable to 
undertake qualitative interviews with the people sent the PPIR communication in order to explore and 
understand patient views of the intervention. 
 
Implications for recruitment practice, public policy and research 
 
It is important to highlight here that whilst we found that directly communicating PPIR using a leaflet to 
potential trial participants was ineffective for improving trial recruitment, this is not the same as PPIR 
being ineffective or harmful to trials in general. Our experience in undertaking this trial, and that of the 
EQUIP host trial is that PPIR is very effective for developing interventions that can be delivered and 
evaluated in trials.  However, we did not actually evaluate this, as the recruitment intervention was 
about direct communication of PPIR to potential participants.  It is quite possible that rather than 
directly communicating PPIR to potential participants, what PPIR achieves in terms of making a trial and 
its interventions more attractive, acceptable and patient-centred is what is important in terms of its 
impact. More rigorous trials are needed to evaluate the impact of PPIR. Here, our findings point to a 
direction of focus for evaluating the impact of PPIR in trials, in informing the design and conduct of 
trials, but not as a means for direct recruitment. Policy makers should be aware that PPIR is not a 
panacea and should fund more systematic evaluations of the impact of PPIR. Findings from this research 
will be sent to the authors of the Cochrane systematic review of interventions to improve recruitment to 
trials, for inclusion in future systematic reviews [11]. 
 
There is some evidence to suggest that PPIR may be effective for improving retention in trials [47]. 
Participants in EQUIP are currently in the follow-up phase. We aim to determine whether direct 
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communication of PPIR improves retention in EQUIP. It is unclear to what extent different versions of 
this intervention might have had different impacts in different trial contexts and patient populations. For 
example, while the PPIR intervention was developed with PPIR partners, it was not user tested with 
potential trial participants. There is some evidence that performance-based user testing of trial 
information can identify strengths and weaknesses in trial information materials and make them fit for 
purpose [94], [95]. Here, the usability, acceptability and accessibility can be improved using semi-
structured interviews and iterative testing cycles [96]. A user-tested version of the intervention may 
have impacted how potential participants responded. A user-tested version of the PPIR intervention is 
currently being evaluated in the Culturally-adapted Family Intervention (CaFI) study recruiting African-
Caribbean people diagnosed with schizophrenia [97]; another version of the intervention is currently 
being evaluated in a study investigating early signs of dementia. Our broad aim is to aggregate the 
results across the different trials to obtain a more precise estimate of effect, as well as to explore the 
effectiveness of the intervention across different research contexts and patient populations. 
 
Our trial highlights the potential benefits of process evaluation in embedded recruitment trials by 
adopting qualitative methods to explore patient use and views of recruitment interventions.  This would 
make it necessary for trialists to obtain the necessary ethical permissions to approach people sent such 
recruitment materials to gain insights into the mechanisms and contexts of these interventions [98].  
There are potential problems, as process evaluation would add significant costs to embedded trials and 
may add significant complexity to the process of embedding a trial, which might act as a barrier to 
adoption. In addition, However, our prior work with people who declined to enter a trial highlights that 
even those who declined to enter a trial reported they do not mind being approached and in addition 
were happy to explore their trial participation decisions [45]. We are currently undertaking an additional 
qualitative study to explore the views of people who are sent a similar PPIR recruitment intervention as 
part of the trial embedded in the CaFI study [97].  
 
Conclusions 
This embedded recruitment trial found no benefits of directly communication PPIR on response, consent 
and enrolment rates. Further embedded trials of these materials are being conducted to explore how 
the impact of the intervention may vary by intervention type, trial context and patient population. A 
more comprehensive cohort of embedded trials of recruitment interventions across the trials portfolio 
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could lead to a rapid development of the evidence base around recruitment, to make trials more 
acceptable and accessible to patients. 
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Additional files 
 
Additional file 1 
• File format: . Microsoft Word document 
• Title of data: Flow diagram for embedded recruitment trial 
• Description of data: an overview of the flow of mental health teams and their patients in the 
embedded trial, based on the ‘guidelines for reporting embedded recruitment trials’, which 
adapts CONSORT for embedded recruitment trials [17]. 
 
Additional file 2 
• File format: Microsoft Word document 
• Title of data: Checklist of items for reporting embedded recruitment trials 
• Description of data: Checklist for reporting embedded recruitment trials, based on the 
‘guidelines for reporting embedded recruitment trials’, which adapts CONSORT for embedded 
recruitment trials [17]. 
 
Additional file 3: 
 File format: Adobe acrobat document 
 Title of Data: Appendix 1: Recruitment intervention advertising patient and public involvement in 
research 
 Description of data: a copy of the recruitment intervention which was mailed to potential trial  
participants 
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